Dana Dildabayeva received her BSc in genetics from Al-Farabi Kazakh National University in 2023 and her MSc in biomedical engineering in precision medicine from the University of Grenoble Alpes through the Erasmus Mundus Joint Programme in 2024. She is currently a research assistant at the Nazarbayev University School of Medicine, where she works on identifying therapeutic targets and mechanisms of drug resistance in breast cancer using genome-wide CRISPR screening and functional genomics. During her master's research at the Centre for Genomic Regulation (CRG) in Barcelona, Spain, she investigated adaptive resistance mechanisms in KRAS-driven pancreatic ductal adenocarcinoma. Her research interests include cancer biology, DNA damage response, PARP inhibitor resistance, CRISPR-based functional genomics, and molecular mechanisms of cancer therapeutic resistance.
Dana Dildabayeva received her BSc in genetics from Al-Farabi Kazakh National University in 2023 and her MSc in biomedical engineering in precision medicine from the University of Grenoble Alpes through the Erasmus Mundus Joint Programme in 2024. She is currently a research assistant at the Nazarbayev University School of Medicine, where she works on identifying therapeutic targets and mechanisms of drug resistance in breast cancer using genome-wide CRISPR screening and functional genomics. During her master's research at the Centre for Genomic Regulation (CRG) in Barcelona, Spain, she investigated adaptive resistance mechanisms in KRAS-driven pancreatic ductal adenocarcinoma. Her research interests include cancer biology, DNA damage response, PARP inhibitor resistance, CRISPR-based functional genomics, and molecular mechanisms of cancer therapeutic resistance.